{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:11:51Z","timestamp":1790514711706,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.nmd.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:14:43Z","timestamp":1602821683000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Gene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead"],"prefix":"10.1016","volume":"31","author":[{"given":"Emma","family":"Heslop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Straub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2020.10.001_bib0001","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nmd.2020.10.001_bib0002","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Acute lymphoblastic leukemia. Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.nmd.2020.10.001_bib0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-1-61737-982-6_2","article-title":"Codon optimization of the microdystrophin gene for Duchene muscular dystrophy gene therapy","volume":"709","author":"Athanasopoulos","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"10","key":"10.1016\/j.nmd.2020.10.001_bib0004","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV microdystrophin gene therapy for duchenne muscular dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2020.10.001_bib0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2020.10.001_bib0006","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: a long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.nmd.2020.10.001_bib0007","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single dose gene replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2020.10.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.05.044","article-title":"Subacute liver failure following gene replacement therapy for spinal muscular atrophy type I","author":"Feldman","year":"2020","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.nmd.2020.10.001_bib0009","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/jgm.390","article-title":"Report of a second serious adverse event in a clinical trial of gene therapy for X linked severe combined immune deficiency (X SCID). Position of the European Society of Gene Therapy (ESGT)","volume":"5","author":"Gansbacher","year":"2003","journal-title":"J Gene Med"},{"key":"10.1016\/j.nmd.2020.10.001_bib0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/imr.12768","article-title":"Cellular therapy: immune related complications","volume":"290","author":"Oved","year":"2019","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.nmd.2020.10.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213649","article-title":"Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents","volume":"14","author":"Landrum Peay","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2020.10.001_bib0012","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-019-1069-6","article-title":"Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best worst scaling experiment in caregivers and adult patients","volume":"14","author":"Paquin","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1016\/j.nmd.2020.10.001_bib0013","doi-asserted-by":"crossref","first-page":"E286","DOI":"10.3390\/molecules25122866","article-title":"Role of lipid-based and polymer-based nonviral vectors in nucleic acid delivery for next generation gene therapy","volume":"25","author":"Wahane","year":"2020","journal-title":"Molecules"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620306386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620306386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:13Z","timestamp":1760775013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620306386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0960896620306386"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.10.001","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy in Duchenne muscular dystrophy: Identifying and preparing for the challenges ahead","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}